Last reviewed · How we verify
Amlodipine + Perindopril
Amlodipine relaxes blood vessels by blocking calcium channels, while perindopril lowers blood pressure by inhibiting angiotensin-converting enzyme (ACE), together reducing hypertension.
Amlodipine relaxes blood vessels by blocking calcium channels, while perindopril lowers blood pressure by inhibiting angiotensin-converting enzyme (ACE), together reducing hypertension. Used for Hypertension, Hypertension in patients with coronary artery disease.
At a glance
| Generic name | Amlodipine + Perindopril |
|---|---|
| Sponsor | Centre for Chronic Disease Control, India |
| Drug class | Calcium channel blocker + ACE inhibitor combination |
| Target | L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that prevents calcium influx into vascular smooth muscle cells, causing vasodilation. Perindopril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. The combination provides complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
- Hypertension in patients with coronary artery disease
Common side effects
- Peripheral edema
- Headache
- Dizziness
- Cough
- Fatigue
- Flushing
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (NA)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Rapid Management of Resistant Hypertension in the Public Health System (Fast Control) (NA)
- Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
- Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension. (PHASE3)
- Observational Cohort Study Evaluating the Effectiveness of an Educational Program (NGAYDAUTIEN) in Combination With Perindopril and Amlodipine Single-Pill Combination in Hypertensive Patients naïve of Antihypertensive Treatments.
- Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine + Perindopril CI brief — competitive landscape report
- Amlodipine + Perindopril updates RSS · CI watch RSS
- Centre for Chronic Disease Control, India portfolio CI